SciSparc Ltd. Form 6-K Summary
Business Context and Reporting Period
SciSparc Ltd., an Israeli foreign private issuer, filed Form 6-K Report No. 2 for September 2026. The report was signed and submitted on September 24, 2026, and furnished a September 23, 2026 press release concerning its subsidiary NeuroThera.
Key Financial Metrics
The filing text does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, capitalization, or other financial metrics.
Material Changes and Corporate Developments
The filing reports that NeuroThera highlighted an enhancement of its U.S. patent portfolio through a collaboration with Clearmind involving combinations of LSD, ketamine, and ibogaine. The filing text does not provide clear details regarding the collaboration’s legal terms, ownership, commercial value, development stage, or expected financial impact.
Guidance, Outlook, Risks, and Unusual Items
No financial guidance or quantified outlook is provided. The filing does not state expected revenue, costs, funding needs, or commercialization timing related to the collaboration. The subject matter involves controlled substances and drug-development activities, which may be subject to regulatory, clinical, intellectual-property, and commercialization risks; however, the filing text does not provide a detailed risk discussion.
Facts Investors Should Verify
- Review Exhibit 99.1 for the full terms and scope of the NeuroThera-Clearmind collaboration.
- Verify the specific U.S. patent applications, grants, claims, ownership, and protection periods involved.
- Determine whether the collaboration creates any licensing revenue, expenses, equity obligations, or other financial commitments.
- Assess the regulatory and clinical status of the LSD, ketamine, and ibogaine combination programs.
- Review subsequent filings for financial effects, funding requirements, or changes to the company’s development strategy.